BioDrugs
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
Ira Jacobs, Danielle Petersel,Lesley G. Shane, Chee-Keng Ng, Carol Kirchhoff, Gregory Finch, Sadiq Lula
Corresponding author: Ira Jacobs; Pfizer Essential Health, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017-5755, USA. Email: ira.jacobs@pfizer.com

Supplementary Fig. S3 Modified-Downs and Black score of abstracts from conference proceedings of RCTs and observational studies (33 studies): oncology[1-11] and chronic inflammatory disease*[10,12-32] studies.



* Aliaga et al,[10] reported data in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, scleroderma, and dermatomyositis, thus was included in both oncology and chronic inflammatory diseases.
RCT randomized control trial

References

1. Markus R, et al. Results of functional testing and pharmacokinetics comparing ABP 215 to bevacizumab. J Clin Oncol. 2015;33: Abstr: 711.
2. Filon O, et al. Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC. 2015 American Society of Clinical Oncology (ASCO) Annual Meeting; 29 May-2 June 2015; Chicago, IL.
3. Orlov SV, et al. Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Amastin in patients. J Clin Oncol. 2014;32: Abstr: e13500
4. Stenina MB, et al. Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients. J Clin Oncol. 2014;32(suppl): Abstr: e11576.
5. Im Y, et al. Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. J Clin Oncol. 2013;31:629.
6. Im Y, et al. Phase I/IIb clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6 [abstract S108]. 2013 (last update 2013). <http://www.biosimilarz.com/wp-content/uploads/2013/03/ct-p06-in-mbc_abstract_st-gallen-2013_13mar2013.pdf. Accessed 22 June 2016>.
7. Alexeev S, Zaritskey A, Volodicheva E, Loginov A, Orlova R, Dvornichenko V et al. Clinical comparability of BCD-020 to innovator rituximab in patients with indolent non-Hodgkin's lymphoma. Haematologica. 2014;99:144-5.
8. Kim SJ, et al. Safety, pharmacokinetic/pharmacodynamic profiles and efficacy of sait101, a biosimilar of rituximab in patients with diffuse large b-cell lymphoma. Haematologica. 2012;97 S317-S8.
9. Flores-Ortiz LF, et al. Physicochemical properties of rituximab. J Liq Chromatogr Relat Technol. 2014;37(10):1438-52.
10. Aliaga L, et al. Pharmacovigilance of anti CD 20 monoclonal antibody biosimilar at the Edgardo Rebagliati Martins Hospital-Peru. Drug Safety. 2013;36:925.
11. Mekhssian K, et al. Application of complementary HRMS methodologies for a thorough biosimilar comparability assessment. American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference; 8-10 June 2015; San Francisco, CA.
12. Yoo DH, et al. Impact of anti-drug antibody on efficacy and safety over week 24 in both CT-P10 and innovator rituximab treatment groups. Arthritis Rheum. 2014;65(suppl 10):S736.
13. Becker J-CP, et al. A Phase I trial comparing PF-05280586 (a potential biosimilar) and rituximab in subjects with active rheumatoid arthritis. Arthritis Rheum. 2014;66:S660-S1.
14. Barile-Fabris LA, et al. Incidence of adverse events in patients treated with intended copies of biologic therapeutic agents in Colombia and Mexico. Arthritis Rheum. 2014;66:S662-S.
15. Bandyopadhyay S. Safety and efficacy of rituximab-biosimilar for the treatment of moderate to severe rheumatoid arthritis patients following the failure of disease-modifying drugs: a case series from Apollo Gleneagles Hospital, Kolkata. Indian Rheumatology Association 29th Annual Conference (IRACON 2013); 6-8 December 2013; Kolkota, Calcutta, India.
16. Kaur P, et al. A randomized, single-blind, single-dose, three-arm, parallel group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab: Results of comparison with adalimumab (EU). Ann Rheum Dis. 2014;73:479.
17. Shin D, et al. A Phase I pharmacokinetic study comparing SB5, an adalimumab biosimilar, and adalimumab reference product (Humira®) in healthy subjects. Ann Rheum Dis. 2015;74:459-60.
18. Kay J, et al. A phase 3, randomized, double-blind, active comparator study of the efficacy and safety of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis. 2014;73:64.
19. Codreanu C, et al. Romanian Registry of Rheumatic Diseases: efficacy and safety of biologic therapy in rheumatoid arthritis. Ann Rheum Dis. 2015;74:458.
20. Gecse K, et al. Biosimilar Infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort. Zeitschrift für Gastroenterologie. 2015;53(05):A11.
21. Kierkus J. Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. Gastroenterology. 2015;148(4 (Suppl 1)):S782-S3.
22. Molnar T, et al. Efficacy of the new infliximab biomarker CT-P13 induction therapy on mucosal healing in ulcerative colitis patients. J Crohns Colitis. 2015;9(Suppl 1):S382-S.
23. Murphy C, et al. Biosimilar but not the same. J Crohns Colitis. 2015;9(Suppl 1):S331-S2.
24. Yoo DH, et al. A randomized, double-blind, three-arm, parallel group, single-dose study to compare the pharmacokinetics, safety, and tolerability of three formulations of infliximab (CT-P13, EU-sourced infliximab and US-sourced infliximab) in healthy volunteers. Arthritis Rheum. 2014;66(suppl):1509.
25. Udata C, et al. A Phase I pharmacokinetics trial comparing PF-06438179 (a potential biosimilar) and infliximab in healthy volunteers (REFLEXTIONS B537-01). Ann Rheum Dis. 2014;73:494.
26. Shin D, et al. A Phase I pharmacokinetic study comparing SB2, an infliximab biosimilar, and infliximab reference product (Remicade®) in healthy subjects. Ann Rheum Dis. 2015;74:703.
27. Bae S-C, et al. A randomized, double-blind, Phase 3 equivalence trial comparing the etanercept biosimilar, HD203, with etanercept (Enbrel (R)), in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA). Arthritis Rheum. 2014;66:S1234-S.
28. Chung H, et al. LBEC0101, An etanercept bisimilar, showed comparable rolerability and pharmacokinetic proles to those of etanercept in healthy male volunteers. Clin Pharmacol Ther. 2014;95:S39-S.
29. Lee YJ, et al. A Phase I pharmacokinetic study comparing SB4, an etanercept biosimilar, and etanercept reference product (Enbrel®) in healthy male subjects. Ann Rheum Dis. 2015;74:718.
30. Moctezuma JF, et al. Comparative, randomized, simple blind to evaluate efficacy and safety of infinitam® (etanercept), associated with methotrexate compared with Enbrel® (etanercept) associated with methotrexate in patients with modeate and severe rheumatoid arthritis. Ann Rheum Dis. 2013;72:A234-A.
31. An Y, et al. Treatment of rheumatoid arthritis with biological DMARDS in China: a multi-center cross-sectional study. Ann Rheum Dis. 2015;74:1302.
32. Santos-Moreno P, et al. Etanar – A etanercept biosimilar is as effective as adalimumab and infliximab in a cohort of real-life of patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:789-90.